Menchi Elena, El Khattabi Charaf, Pochet Stéphanie, Denis Olivier, Amighi Karim, Wauthoz Nathalie
Unit of Pharmaceutics and Biopharmaceutics, Department of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles,1050 Brussels, Belgium.
Unit of Pharmacology, Pharmacotherapy and Pharmaceutical Care, Department of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles, 1050 Brussels, Belgium.
Pharmaceuticals (Basel). 2022 Aug 3;15(8):963. doi: 10.3390/ph15080963.
The co-administration of a long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), has been shown to be beneficial in the management of non-communicable chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The resulting relaxation of the airways can be synergistically enhanced, reducing symptoms and optimizing lung function. This provides an insight into more effective treatments. In this study, the LABAs formoterol fumarate dihydrate (FOR) and indacaterol maleate (IND) were each associated with tiotropium bromide monohydrate (TIO) to assess their synergistic potential. This was done using an appropriate ex vivo model of isolated perfused guinea pig tracheal rings, and pharmacological models of drug interaction. Among the dose ratios studied for both types of combination, a higher synergistic potential was highlighted for FOR/TIO 2:1 (). This was done through three steps by using multiple additions of drugs to the organ baths based on a non-constant dose ratio and then on a constant dose ratio, and by a single addition to the organ baths of specific amounts of drugs. In this way, the synergistic improvement of the relaxant effect on the airways was confirmed, providing a basis for improving therapeutic approaches in asthma and COPD. The synergy found at this dose ratio should now be confirmed on a preclinical model of asthma and COPD by assessing lung function.
长效β2受体激动剂(LABA)与长效毒蕈碱拮抗剂(LAMA)联合使用已被证明对哮喘和慢性阻塞性肺疾病(COPD)等非传染性慢性呼吸道疾病的治疗有益。由此产生的气道舒张作用可得到协同增强,减轻症状并优化肺功能。这为更有效的治疗方法提供了思路。在本研究中,将富马酸福莫特罗二水合物(FOR)和马来酸茚达特罗(IND)这两种LABA分别与一水合噻托溴铵(TIO)联合,以评估它们的协同潜力。这是通过使用合适的离体灌注豚鼠气管环的体外模型以及药物相互作用的药理学模型来完成的。在所研究的两种组合的剂量比中,FOR/TIO 2:1显示出更高的协同潜力()。这是通过三个步骤完成的,即基于非恒定剂量比然后基于恒定剂量比向器官浴中多次添加药物,以及向器官浴中单次添加特定量的药物。通过这种方式,证实了对气道舒张作用的协同改善,为改善哮喘和COPD的治疗方法提供了依据。现在应通过评估肺功能,在哮喘和COPD的临床前模型上确认该剂量比下的协同作用。